Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.56 |
| ▸ | CES2 | O00748 | 5/20 | 0.39 |
| ▸ | CES1 | P23141 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL183581 | 0.98 | FAAH (0.59) | FAAHCES2CES1ALDH1A1NPSR1 | |
| SCHEMBL6312371 | 0.94 | FAAH (0.53) | FAAHCES2CES1ALDH1A1NPSR1 | |
| SCHEMBL10704882 | 0.87 | FAAH (0.69) | FAAHCES2CES1ALDH1A1NPSR1 | |
| SCHEMBL2085613 | 0.85 | FAAH (0.47) | FAAHALDH1A1NPSR1GLO1CYP1A2 | |
| SCHEMBL18101453 | 0.84 | FAAH (0.60) | FAAHCES2CES1ALDH1A1NPSR1 | |
| Toluene SCHEMBL27596438 | 0.84 | FAAH (0.47) | FAAHCES2CES1ALDH1A1GAA | |
| SCHEMBL28035998 | 0.83 | FAAH (0.56) | FAAHCES2CES1ALDH1A1NPSR1 | |
| SCHEMBL3014656 | 0.83 | FAAH (0.76) | FAAHCES2CES1ALDH1A1HSD17B10 | |
| SCHEMBL28883762 | 0.81 | FAAH (0.50) | FAAHCES2CES1ALDH1A1TSHR | |
| SCHEMBL1088961 | 0.81 | FAAH (0.79) | FAAHCES2CES1ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4003988-B1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | SERVIER LAB (FR) | 2026-05-20 | — | — | EP | disclosed |
| CN-114450283-B | 3, 6-Diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their use as pro-apoptotic agents | 法国施维雅药厂 | 2024-05-07 | — | — | CN | disclosed |
| US-20220289734-A1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | LES LABORATOIRES SERVIER (FR) | 2022-09-15 | — | — | US | disclosed |
| EP-4003988-A1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | Les Laboratoires Servier (FR) | 2022-06-01 | — | — | EP | disclosed |
| CN-114450283-A | 3, 6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their use as pro-apoptotic agents | 法国施维雅药厂 | 2022-05-06 | — | — | CN | disclosed |
| WO-2021018857-A1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | LES LABORATOIRES SERVIER (FR) | 2021-02-04 | — | — | WO | disclosed |
| US-9067928-B2 | Compounds and methods of use | ABBVIE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| EP-2373163-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2376085-B1 | COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2014-02-26 | — | — | EP | disclosed |
| US-20140005190-A1 | COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-01-02 | — | — | US | disclosed |
| EP-2240478-A1 | SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2010-10-20 | — | — | EP | disclosed |
| US-20100210622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100190782-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
| WO-2010080503-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2009080291-A1 | SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| EP-2072516-A1 | Substituted imidazopyridine derivates as Melancortin-4 receptor antagonists | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2009-06-24 | — | — | EP | disclosed |
| WO-2008098096-A1 | ANTI-CYTOKINE HETEROCYCLIC COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008098096-A1 | ANTI-CYTOKINE HETEROCYCLIC COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-14 | — | — | WO | disclosed |
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BCL2A1, BAX, BCL2 | FAAH 4162/4885CES2 2628/4885CES1 3742/4885 |
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | FAAH 3283/4885CES2 3988/4885CES1 4205/4885 |
| US-20140005190-A1 | COMPOUNDS AND METHODS OF USE | BCL2A1, BCL2, BAX | FAAH 4383/4885CES2 2175/4885CES1 3420/4885 |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | FAAH 3283/4885CES2 3988/4885CES1 4205/4885 |
| US-20220289734-A1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | CASP3, BAX, CASP2 | FAAH 676/4885CES2 3527/4885CES1 1906/4885 |
| US-20100190782-A1 | COMPOUNDS AND METHODS OF USE | BCL2A1, BCL2, BAX | FAAH 4383/4885CES2 2175/4885CES1 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.